These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34449935)

  • 1. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
    Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
    Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
    Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
    Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
    Julia E; Salles G
    Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
    Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
    Fu H; Cheng L; Sa R; Jin Y; Chen L
    J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
    Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
    Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epigenetic modification as a therapeutic approach for B-cell lymphoma].
    Nishikori M; Takaori-Kondo A
    Rinsho Ketsueki; 2022; 63(4):313-321. PubMed ID: 35491222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
    Brach D; Johnston-Blackwell D; Drew A; Lingaraj T; Motwani V; Warholic NM; Feldman I; Plescia C; Smith JJ; Copeland RA; Keilhack H; Chan-Penebre E; Knutson SK; Ribich SA; Raimondi A; Thomenius MJ
    Mol Cancer Ther; 2017 Nov; 16(11):2586-2597. PubMed ID: 28835384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
    Lue JK; Amengual JE
    Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
    Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.
    Mondello P; Ansell SM
    Expert Opin Pharmacother; 2022 Feb; 23(3):295-301. PubMed ID: 34904909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.
    Tan X; Zhang Z; Liu P; Yao H; Shen L; Tong JS
    Cell Death Dis; 2020 Dec; 11(12):1061. PubMed ID: 33311453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
    Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
    Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and pharmacokinetics of tazemetostat.
    Orleni M; Beumer JH
    Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
    Qi L; Lindsay H; Kogiso M; Du Y; Braun FK; Zhang H; Guo L; Zhao S; Injac SG; Baxter PA; Su JM; Xiao S; Erickson SW; Earley EJ; Teicher B; Smith MA; Li XN
    Lab Invest; 2022 Feb; 102(2):185-193. PubMed ID: 34802040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
    Otsuka Y; Nishikori M; Arima H; Izumi K; Kitawaki T; Hishizawa M; Takaori-Kondo A
    Mol Immunol; 2020 Mar; 119():35-45. PubMed ID: 31962268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.
    Palomba ML; Cartron G; Popplewell L; Ribrag V; Westin J; Huw LY; Agarwal S; Shivhare M; Hong WJ; Raval A; Chang AC; Penuel E; Morschhauser F
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):504-512. PubMed ID: 35151584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.